Engineering CAR-T cells to remodel the mucin-rich cancer cell glycocalyx
Park, S.; Ho, C.; Wolff, A. N.; Fan, Y.; Bouffard, A. A.; Paek, J.; Mucci, A.; Berger, T. R.; Paszek, M. J.; Maus, M. V.
Show abstract
The dense glycocalyx of cancer cells can restrict immune-cell access to surface antigens and limit CAR-T cell activity. Here, we show that mucin density and epitope position determine how glycocalyx remodeling affects CAR-T cell recognition and killing. We identify KLK5 as a human protease that cleaves tumor-associated mucins, increases access to membrane-proximal antigens, and enhances CAR-T cell function. We then engineer CAR-T cells to display or secrete KLK5, enabling remodeling of the tumor glycocalyx during antigen recognition. KLK5-engineered CAR-T cells improved tumor control across multiple xenograft models, and KLK5-secreting MUC17 CAR-T cells produced the strongest in vivo benefit, prolonging survival compared with conventional MUC17 CAR-T cells. These findings show that CAR-T cells can be engineered to breach the mucin-rich glycocalyx while preserving accessible target epitopes.
Matching journals
The top 10 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors 95%
- Engineering B cells to Express Fully Customizable Antibodies with Enhanced Fc Functions 95%
- In vivo CRISPR screens reveal Serpinb9 and Adam2 as regulators of immune therapy response in lung cancer 94%
Similar papers in this journal
Similar papers in this journal
- A general approach for selection of epitope-directed binders to proteins 95%
- Phenotypic determinism and stochasticity in antibody repertoires of clonally expanded plasma cells 94%
- The Spread of Interferon-γ in Melanomas is Highly Spatially Confined, Driving Non-Genetic Variability in Tumor Cells 93%
Similar papers in this journal
- Decoy Antibodies Block Extracellular HSP70, Prevent Self Signaling and Inhibit Melanoma Cell Survival 94%
- Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals 94%
- Extremely potent monoclonal antibodies neutralize Omicron and other SARS-CoV-2 variants 94%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.